Drugs / BMS-986166
BMS-986166
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05409157 | Jun → Oct 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04934696 | Aug 2021 → Jan 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04956627 | Jul 2021 → Apr 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04965402 | Jul 2021 → Feb 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03038711 | Feb → Aug 2017 | ulcerative colitis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02790125 | Jul 2016 → Nov 2017 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05014438 | Aug 2021 → Aug 2022 | atopic eczema | Bristol-Myers Squibb | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-09-30 | Bristol-Myers Squibb | Results Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases bms.com ↗
BMS-986166, a Novel S1PR1,4,5 Modulator, is Highly Efficacious in a Mouse Model of Atopic Dermatitis |
All press releases naming this drug 1 release
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986166 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02790125 ↗ |
| Known as | BMS-986166 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4649457 ↗ |
| Known as | BMS-986166-04 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4649457 ↗ |
| Modality | Small molecule | — CHEMBL4649457 ↗ |
| Route | Oral | “Single oral dose of solution as specified” NCT02790125 ↗ |